# OMass Therapeutics

> Oxford biotech developing small-molecule medicines in endocrinology and immunology.

## Why it is interesting

The financing can test whether discovery productivity translates into differentiated human clinical outcomes; round size is not evidence of efficacy or approval.

## Profile

- **Latest funding:** Series C — $310M (£230M) (October 15, 2026)
- **Latest known valuation:** Undisclosed (October 15, 2026)
- **Total disclosed equity funding:** $310M
- **Stage:** growth
- **Status:** private
- **Industries:** healthtech, biotech-life-sciences
- **Coverage:** full
- **Last updated:** 2026-10-15T17:17:00Z
- **Latest funding investors:** Bain Capital Life Sciences, Forbion, Novo Holdings, Janus Henderson Investors, SV Health Investors, Jefferson Life Sciences, Syncona, Oxford Science Enterprises, GV, Northpond Ventures, Sanofi Ventures, British Business Bank, University of Oxford

## Funding history

- Series C · $310M (£230M) · October 15, 2026
  Source: https://www.omass.com/2026/10/15/omass-therapeutics-announces-310-million-series-c-financing-to-advance-portfolio-of-small-molecule-therapeutics-in-endocrinology-and-immunology/

## Investors in our directory

- https://venturecapitaltracker.com/fund/bain-capital-life-sciences
- https://venturecapitaltracker.com/fund/forbion
- https://venturecapitaltracker.com/fund/novo-holdings
- https://venturecapitaltracker.com/fund/oxford-science-enterprises
- https://venturecapitaltracker.com/fund/gv

## Related articles

- https://venturecapitaltracker.com/omass-310m-series-c-clinical-development

**By:** [Venture Capital Tracker](https://venturecapitaltracker.com/editorial-policy)
**Last updated:** October 15, 2026

**Editorial note:** AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.

---
Source: https://venturecapitaltracker.com/startup/omass-therapeutics